Compositions and methods for treating transthyretin (ttr) mediated amyloidosis

作者: Jared Gollob

DOI:

关键词: Human patientMedicineTransthyretinAmyloidosisPathology

摘要: Disclosed herein are methods for treating hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in a human patient need thereof by administering an effective amount of transthyretin (TTR)-inhibiting composition.

参考文章(107)
Peter M. Simonson, SPINAL IMPLANT ASSEMBLIES ,(2012)
Hans-Wilhelm Verholt, Herbert Fischer, Konrad Engelskirchen, Process for the production of polysaccharide-based polycarboxylates ,(1993)
Stuart Milstein, Qingmin Chen, Gregory Hinkle, Rene Alvarez, Dinah Wen-Yee Sah, Compositions and methods for inhibiting expression of transthyretin ,(2009)
Robert J. Suhadolnik, Wolfgang Pfleiderer, Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof ,(1993)
Muthiah Manoharan, Tracy Zimmermann, Klaus Charisse, Satyanarayana Kuchimanchi, Martin Maier, Kallanthottathil G. Rajeev, RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases ,(2012)
Alfonso R. Gennaro, Joseph P. Remington, Remington's pharmaceutical sciences Published in <b>1975</b> in Easton Pa) by Mack. ,(1985)
Eugeny Kvasyuk, Gennady Matsuka, Zenovy Tkachuk, Igor Mikhailopulo, (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response ,(1991)